• Explore /
  • Poster
  • / Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.

Phase III study of pembrolizumab (pembro) plus enzalutamide (enza) and androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): KEYNOTE-991.

Abstract Poster

Authors

null

Christian Gratzke

University Medical Center Freiburg, Freiburg, Germany

Christian Gratzke , Joseph E Burgents , Cuizhen Niu , Christian Heinrich Poehlein , Charles G. Drake

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT04191096

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS5595)

DOI

10.1200/JCO.2020.38.15_suppl.TPS5595

Abstract #

TPS5595

Poster Bd #

176

Abstract Disclosures

Similar Posters

First Author: Christian Gratzke

First Author: Julie Nicole Graff

First Author: Gero Kramer

First Author: Daniel Peter Petrylak